Drugs / VT30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04409145 | Oct 2020 → Apr 2022 | lymphatic malformation, vascular malformation | Venthera, Inc., a BridgeBio company | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-10 | Eidos Therapeutics, a BridgeBio company | Results bridgebio pharma affiliate venthera presents preliminary results from clinical trial of vt30 (bbp-681) for venous, lymphatic, and venolymphatic malformations bridgebio.com ↗
The data presented are preliminary results from an open-label, dose-finding study of VT30 topical gel in patients with cutaneous VM/LM/VLM lesions associated with mutations that result in dysregulated PI3K activation. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-10 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma affiliate venthera presents preliminary results from clinical trial of vt30 (bbp-681) for venous, lymphatic, and venolymphatic malformations bridgebio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04409145 ↗ |
| Action | Inhibit | “VT30 is a PI3K-inhibitor prodrug” NCT04409145 ↗ |
| Route | Topical | “formulated as a topical gel” NCT04409145 ↗ |